How COVID misinformation goes viral—and how to beat it at its own game

People tend to perceive themselves as less swayed than others by COVID-19 misinformation, and the gap helps explain why some people are more open than others to lockdowns, mandatory masks and other governmental interventions.

The findings are from an online survey designed and analyzed by two communications scholars, Yang Cheng, PhD, MBA, of North Carolina State University and Luo Yunjuan, PhD, of South China University of Technology.

Their survey drew around 1,800 completed responses last April, and their peer-reviewed report is running in Online Information Review.

Cheng and Yunjuan based their COVID-specific hypothesis on the third-person effects theory. This posits that individuals have personal biases causing them to believe others are more affected than themselves by messages from mass media.

“Negative affections toward health misinformation directly affected public support for governmental restrictions rather than corrective action,” the authors conclude. “Support for governmental restrictions could further facilitate corrective action.”

Coverage of the study by N.C. State’s news operation notes that COVID misinformation often elicits feelings of fear, worry, disgust and other negative emotions.

Cheng says this effect can motivate the misinformed to perpetuate two deleterious chains of action.

“First, people are likely to act on content that evokes negative emotions, and that includes sharing information on social media,” she says. “Second, messages that are focused on emotions are more easily transmitted on social media than content that is neutral, such as abstract scientific information.”

Cheng suggests a solution may lie in scientific communicators’ willingness to show some messaging savvy.

“Since fear, worry or other negative emotions can facilitate information seeking or encourage people to avoid specific behaviors during a crisis,” she says, “communicators may want to consider using these emotional messages to convey accurate information about COVID-19 and public health.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.